RGEN logo

Repligen Corporation (RGEN)

$162.18

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RGEN

Market cap

$10.37B

EPS

-0.2

P/E ratio

--

Price to sales

10.84

Dividend yield

--

Beta

1.116803

Price on RGEN

Previous close

$162.78

Today's open

$162.78

Day's range

$160.27 - $165.34

52 week range

$100.99 - $198.87

Profile about RGEN

CEO

Olivier Loeillot

Employees

2000

Headquarters

Waltham, MA

Exchange

Nasdaq Global Select

Shares outstanding

63923738

Issue type

Common Stock

RGEN industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RGEN

Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Repligen Corporation (RGEN) Presents at Jefferies Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • 6 hours ago

news preview

AMG TimesSquare Small Cap Growth Fund Q3 2026 Portfolio Activity

During this quarter, AMG TimesSquare Small Cap Growth Fund outperformed the Russell 2000® Growth Index as the market rewarded the quality characteristics our process emphasizes. We benefited most from our holdings in the Information Technology, Financials, and Consumer Staples sectors, while positioning in the Industrials, Health Care, and Consumer Discretionary sectors offset part of the gain. Each of our largest contributors was driven by company-specific fundamentals, including solid results and business momentum, and, in two cases, making acquisitions we viewed as strategically or financially attractive.

news source

Seeking Alpha • Nov 15, 2026

news preview

Voya Small Cap Growth Strategy Q3 2026 Contributors And Detractors

For the quarter ended September 30, 2026, the Fund underperformed the Index on a NAV basis, due to stock selection. Negative stock selection in the industrials, financials, and materials sectors was the leading detractor from performance along with an overall negative allocation effect. Stock selection in the consumer staples and real estate sectors and holding cash were the largest contributors to performance.

news source

Seeking Alpha • Nov 12, 2026

news preview

Alger Mid Cap 40 ETF Q3 2026 Portfolio Review

Twist Bioscience Corp., Cloudflare Inc., and Repligen Corporation were among the top contributors to performance. We believe Cloudflare's extensive network and expanding product portfolio position it to benefit from rising internet traffic, growing cybersecurity needs, and enterprise adoption of AI. FTAI shares detracted from performance during the quarter despite continued growth in its engine products business and progress on adapting mature aircraft engines for data center power generation.

news source

Seeking Alpha • Nov 12, 2026

news preview

Repligen: 3 Key Takeaways for Long-Term Investors

Repligen delivered revenue of $209 million in the third quarter. BioLife is expected to contribute $24 million in fourth-quarter revenue.

news source

The Motley Fool • Nov 5, 2026

news preview

Repligen Corporation to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN), today announced that it will participate in the Jefferies Global Healthcare Conference in London, UK. Olivier Loeillot, President and Chief Executive Officer, will participate in an analyst-led discussion on November 18th at 2:00 p.m. GMT.

news source

GlobeNewsWire • Nov 4, 2026

news preview

Baron SMID Cap ETF Q3 2026 Contributors And Detractors

Baron SMID Cap ETF returned -2.87% (NAV) in the third quarter, outperforming its benchmark, the Russell 2500 Growth Index, which returned -10.35%. Top contributors were Rubrik, Inc., Tempus AI, Inc., and Netskope, Inc. Top detractors were Axon Enterprise, Inc., Forgent Power Solutions, Inc., and Mercury Systems, Inc.

news source

Seeking Alpha • Nov 3, 2026

news preview

Repligen Announces $1 Billion Private Convertible Senior Notes Transaction

WALTHAM, Mass., Oct. 30, 2026 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) (“Repligen”), today announced that it entered into privately negotiated exchange and/or subscription agreements with certain holders of its outstanding 1.00% Convertible Senior Notes due 2028 (the “2028 Notes”) and certain new investors, pursuant to which Repligen will issue $1.0 billion aggregate principal amount of 0.25% Convertible Senior Notes due 2031 (the “New Notes”). Approximately $541.4 million principal amount of the New Notes will be issued in exchange for approximately $456.8 million principal amount of 2028 Notes (the “Exchange Transactions”) and approximately $458.6 million principal amount of the New Notes will be issued for cash (the “Subscription Transactions”, and together with the Exchange Transactions, the “Transactions”). The conversion price for the New Notes will initially be approximately $226.37 per share of Repligen's common stock, which represents a conversion premium of approximately 20% over the closing price of Repligen's common stock on October 29, 2026, subject to customary anti-dilution adjustments. Following the closing of the Transactions, which is expected to occur on or about November 6, 2026, subject to customary closing conditions, approximately $143.2 million in aggregate principal amount of 2028 Notes will remain outstanding with terms unchanged.

news source

GlobeNewsWire • Oct 30, 2026

news preview

Conestoga Micro Cap Composite: Q3 2026 Leaders, Laggards, Buys And Sells

We remain encouraged by the operational performance of the Micro cap companies held in portfolios. TWST shares surged as a strong fiscal 3Q highlighted accelerating demand across several of the company's end markets. TKNO management responded to the stronger first half by substantially raising its full-year revenue outlook.

news source

Seeking Alpha • Oct 30, 2026

news preview

What Repligen (RGEN) Said on Its Q3 Earnings Call

Repligen NASDAQ: RGEN reported record third-quarter 2026 revenue of $209 million, surpassing its prior quarterly peak set in the second quarter of 2022, as growth in its Proteins, Chromatography and Analytics franchises offset weakness in Filtration.

news source

MarketBeat • Oct 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Repligen Corporation

Open an M1 investment account to buy and sell Repligen Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RGEN on M1